Breaking Finance News

Spectranetics (NASDAQ:SPNC) stock price target upped to $30.00, reported today by UBS Securities

In a report announced on 8/03/2016 UBS Securities upped the target price of Spectranetics (NASDAQ:SPNC) from $10 to $30 reporting a possible upside of 0.30%.

Previously on 7/29/2016, Needham released a statement about Spectranetics(NASDAQ:SPNC) upped the target price from $21.00 to $27.00 that suggested an upside of 0.16%.

Having a price of $23.09, Spectranetics (NASDAQ:SPNC) traded 1.02% higher on the day. The last stock price is up 28.90% relative to the 200-day average, compared with the S&P 500 which has decreased -0.01% over the date range. SPNC has registered a 50-day moving average of $24.18 and two hundred day average of $19.12. Trade volume was was down over the average, with 372,857 shares of SPNC changing hands under the typical 471,336 shares.

Performance Graphic:

Spectranetics (NASDAQ:SPNC)

Spectranetics has a 52 week low of $10.65 and a 52 week high of $25.81 . The company’s market capitalization is presently $0.0.

In addition to UBS Securities reporting it’s stock price target, a total of 11 analysts have issued a report on SPNC. The 12-month target is $20.05 with four firms rating the company a strong buy, four firms rating the company a buy, two firms rating the stock a hold, one brokerage rating the stock to underperform, and finally 0 brokeragesrating the company as sell.

General Company Details For Spectranetics (NASDAQ:SPNC)

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads. Its geographic segments are U.S. Medical and International Medical. Its product offerings in U.S. Medical segment include medical devices used in minimally invasive procedures within the cardiovascular system, including fiber-optic devices and non-fiber-optic products (disposables), an excimer laser system (equipment) and the service of the excimer laser system (service). Its products are used in multiple vascular procedures, including peripheral atherectomy, crossing arterial blockages, and coronary atherectomy and thrombectomy. Its International Medical segment is primarily engaged in distribution activities.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *